Detalhe da pesquisa
1.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med
; 386(4): 316-326, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081280
2.
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Lancet
; 398(10315): 1984-1996, 2021 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34767764
3.
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis
; 80(8): 1004-1013, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906853
4.
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
N Engl J Med
; 377(16): 1525-1536, 2017 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045207
5.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
N Engl J Med
; 377(16): 1537-1550, 2017 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045212
6.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Ann Rheum Dis
; 79(11): 1400-1413, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32759265
7.
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Curr Ther Res Clin Exp
; 93: 100601, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32983284
8.
The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Rheumatology (Oxford)
; 58(2): 197-205, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29618084
9.
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritisâ©.
Int J Clin Pharmacol Ther
; 57(9): 464-473, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31319908
10.
Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.
Rheumatology (Oxford)
; 57(8): 1390-1399, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718421
11.
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 76(8): 1340-1347, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28130206
12.
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
Clin Exp Rheumatol
; 34(3): 430-42, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27156561
13.
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
N Engl J Med
; 367(6): 495-507, 2012 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22873530
14.
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Arthritis Rheum
; 64(4): 970-81, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22006202
15.
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Arthritis Rheum
; 64(3): 617-29, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21952978
16.
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis.
ACR Open Rheumatol
; 5(12): 632-643, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37775977
17.
Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial.
Rheumatol Ther
; 10(4): 1001-1020, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37331992
18.
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Lancet Rheumatol
; 3(4): e270-e283, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38279411
19.
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Lancet Rheumatol
; 3(1): e28-e39, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38273637
20.
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Rheumatol Ther
; 7(3): 553-580, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32506317